High-Potency Topical Corticosteroids
High-potency topical corticosteroids play four primary roles in urology: (1) first-line conservative therapy for phimosis (physiologic and pathologic) — reducing the need for circumcision; (2) first-line treatment for genital lichen sclerosus and balanitis xerotica obliterans (BXO) with indefinite maintenance; (3) standard management of genital lichen planus, psoriasis, Zoon balanitis, and labial adhesions; and (4) intralesional or intravesical triamcinolone in selected urologic settings (Hunner lesions, refractory LS).[1][2][3][4]
For related agents, see Topical calcineurin inhibitors, Intralesional corticosteroids, Platelet-rich plasma, and the clinical Lichen sclerosus article.
Potency classification and genital prescribing principles
The US 7-class potency system governs appropriate genital prescribing. Genital skin is thin and highly absorptive — potency selection must balance efficacy against atrophy risk.[5][6]
| US class | Potency | Agents used in urology |
|---|---|---|
| I — Super-high | Very high | Clobetasol propionate 0.05%, halobetasol propionate 0.05% |
| II — High | High | Betamethasone dipropionate 0.05%, fluocinonide 0.05%, desoximetasone 0.25% |
| III–V — Medium | Medium | Betamethasone valerate 0.1%, mometasone furoate 0.1%, triamcinolone acetonide 0.1%, fluticasone propionate 0.05% |
| VI–VII — Low | Low | Hydrocortisone 1–2.5%, desonide 0.05%, alclometasone 0.05% |
Core genital-use principles:
- AAFP and AAD classify the genitalia as thin-skin sites with enhanced percutaneous absorption[5]
- Low-potency agents (VI–VII) are appropriate for routine genital dermatoses (contact dermatitis, genital psoriasis)
- High-potency agents (I–II) are reserved for specific conditions — lichen sclerosus and lichen planus — where benefit clearly outweighs atrophy risk
- Ointments are preferred over creams on genital and mucosal surfaces — better barrier, no preservatives/fragrances, enhanced drug delivery[5][7]
Phimosis — the primary urologic application
Guideline positioning
Topical corticosteroids are first-line before circumcision in EAU 2018, CUA 2017, and NICE-accredited guidelines. Three cost-effectiveness analyses confirm superiority over primary circumcision as initial management.[1]
Dual mechanism
- Anti-inflammatory: phospholipase-A2 inhibition → reduced prostaglandins / leukotrienes → ↓ edema, fibrin, capillary dilation, fibroblast proliferation
- Tissue remodeling: inhibition of epidermal proliferation and collagen synthesis → skin thinning + increased elasticity, allowing the stenotic preputial ring to stretch[1]
Cochrane 2024 — 14 RCTs, n = 1,459[1]
| Outcome | Effect vs placebo | RR (95% CI) |
|---|---|---|
| Complete resolution (4–8 wk) | +436 per 1,000 | RR 2.73 (1.79–4.16) |
| Partial resolution (4–8 wk) | +202 per 1,000 | RR 1.68 (1.17–2.40) |
| Long-term complete resolution (≥6 mo) | +528 per 1,000 | RR 4.09 (2.80–5.97) |
| Adverse effects | No difference | RR 0.28 (0.03–2.62) |
Subgroup analysis suggested topical corticosteroids may be more effective in younger boys (<7 y); certainty of evidence was low across outcomes.[1]
Which corticosteroid is best — Sridharan 2021 network meta-analysis
- Overall remission: methylprednisolone > hydrocortisone > betamethasone had the highest probability of being "best"
- Complete remission: betamethasone > hydrocortisone ranked highest
- Very-high-potency agents (beclomethasone, clobetasol) were not superior to medium-potency agents
- Authors concluded hydrocortisone (low-potency) should be preferred given comparable efficacy and better safety[8]
Yang 2005 head-to-head RCT — betamethasone valerate 0.06% (high) vs clobetasone butyrate 0.05% (moderate): comparable response rates 81.3% vs 77.4% (p = 0.63) — supports moderate-potency agents.[9]
Campos 2026 multicenter cohort — n = 235
Across 12 hospitals, betamethasone 0.05% BID × 8 weeks achieved 68% success, with no differences across phimosis severity grades or age groups. The only significant predictor of failure was altered preputial skin appearance (success 72% healthy skin vs 29% altered skin; p = 0.007) — a surrogate for underlying BXO / LS. Adherence, age, symptoms, and prior balanitis were not predictive.[10]
Adult phimosis — thinner literature
Lygas 2022 systematic review found significant heterogeneity and limited trial data. Topical steroids appear probably safe with some potential to reduce LS-associated phimosis signs / symptoms, but good-quality RCT data with patient-reported outcomes are needed.[11]
Standard phimosis protocol[1][9][10]
| Parameter | Recommendation |
|---|---|
| Agent | Betamethasone 0.05% ointment (most studied); mometasone 0.05% ointment is an alternative |
| Application | Thin layer to the stenotic distal prepuce |
| Technique | Gentle retraction of foreskin as far as possible without pain before application |
| Frequency | Twice daily |
| Duration | 4–8 weeks (most protocols use 8 weeks) |
| Post-treatment | Continue gentle retraction exercises and hygiene after course completion |
| Partial response | May repeat a second 4–8-week course |
| Failure / refractory | Refer for circumcision or preputioplasty |
| Expected success | 65–96% depending on definition and severity |
Lichen sclerosus / BXO — the most important chronic indication
Overview
LS is a chronic inflammatory dermatosis predominantly affecting the anogenital region. In males it is called balanitis xerotica obliterans (BXO) and typically involves the foreskin and glans — causing phimosis, meatal stenosis, and potentially urethral stricture. Mean age in boys is 8 years; BXO is the most common cause of pathologic phimosis in boys >9 y.[12][7]
First-line — ultrapotent / potent topical corticosteroids
The German S3 guideline 2026, ACOG Practice Bulletin 224, British Association of Dermatologists, and Cochrane review all recommend ultrapotent or potent topical corticosteroids as first-line for genital LS regardless of age or sex.[13][3][14] Clobetasol propionate 0.05% ointment is the most studied and widely used agent.
Cochrane 2011 review — Chi et al., 7 RCTs, n = 249[14][15]
- Clobetasol 0.05% vs placebo: participant-rated improvement RR 2.85 (95% CI 1.45–5.61); investigator-rated SMD 5.74 (95% CI 4.26–7.23)
- Mometasone 0.05% vs placebo: improved clinical grade of phimosis (SMD −1.04; 95% CI −1.77 to −0.31)
- Topical testosterone, DHT, and progesterone showed no benefit; topical testosterone worsened symptoms when used as maintenance after clobetasol
- Pimecrolimus was comparable to clobetasol for symptom relief but less effective for gross appearance (SMD −1.64; 95% CI −2.40 to −0.87)
Male-genital LS conservative management — Shieh 2024 systematic review
Across 17 studies of histologically confirmed penile / urethral LS:[2]
- Topical corticosteroids remain the mainstay of conservative management
- Alternative / adjunctive options: tacrolimus, PRP, CO₂ laser
- Escalation appropriate when corticosteroids are insufficient
Treatment protocol[3][7][14]
| Phase | Regimen | Duration |
|---|---|---|
| Induction | Clobetasol 0.05% ointment BID | Until active lesions regress (4–8 wk typical) |
| Taper | Clobetasol 0.05% ointment QD or QOD | 2–4 wk |
| Maintenance | Clobetasol 1–2×/wk OR step down to betamethasone 0.1% ointment | Indefinite (LS is chronic) |
| Monitoring | Follow-up at 3 months to assess response and application technique | Ongoing |
| Refractory | Topical calcineurin inhibitors OR intralesional triamcinolone | — |
BXO-specific considerations in males
- Early / intermediate BXO responds to topical corticosteroids; advanced / irreversibly scarred phimosis does not respond and requires circumcision[1][12]
- German S3 guideline 2026 — in LS-associated phimosis unresponsive to standard therapy, circumcision with complete foreskin removal is indicated[13]
- Meatal stenosis may require meatotomy or meatoplasty; topical steroids are adjunctive post-procedure[12]
- Long-term surveillance is important — LS carries an increased SCC risk in affected tissue[12][15]
Lichen planus
Chronic autoimmune inflammatory condition. In uncircumcised men, genital LP can cause adhesions and phimosis; in women, erosive vulvovaginal LP can cause scarring, synechiae, and vaginal stenosis.[16][17]
Treatment
| Line | Agent |
|---|---|
| First-line | Clobetasol 0.05% ointment — cutaneous, genital, and mucosal erosive LP[3][16][17] |
| Erosive vulvar LP | Clobetasol BID attenuated symptoms in 71% in a prospective cohort; complete resolution (except scarring) uncommon[16] |
| Synechiae prevention | Vaginal dilators (women); foreskin retraction (men) to prevent adhesions[16] |
| Second-line | Tacrolimus 0.1% — particularly for vulvovaginal LP[3][17] |
| Refractory | Intralesional corticosteroids; systemic corticosteroids; acitretin; mycophenolate[3][17] |
| Uncircumcised men | Circumcision usually recommended — LP occurs less frequently in circumcised men[16] |
Genital psoriasis
Affects up to 63% of psoriasis patients at some point; frequently underdiagnosed because patients are neither questioned nor examined for this manifestation.[18]
Treatment principles unique to genital skin:[19][18]
- Warm moist environment enhances drug penetration and irritation / atrophy risk
- Low-potency corticosteroids (classes VI–VII) are preferred
- Calcineurin inhibitors (tacrolimus 0.1%, pimecrolimus 1%) — no atrophy; useful as steroid-sparing maintenance[20][18]
- Vitamin D analogues (calcipotriene) may cause genital irritation; calcitriol better tolerated[18]
- Proactive maintenance after clearing: twice-weekly low-potency corticosteroid or calcineurin inhibitor to prevent relapse[19]
Zoon balanitis (plasma cell balanitis)
Idiopathic chronic inflammatory condition of the glans and prepuce — "cayenne-pepper" speckled plaques, almost exclusively in uncircumcised men.[21][22]
Treatment hierarchy:
- Circumcision — considered curative[22][23]
- Topical corticosteroids — Trimovate cream (clobetasone butyrate + oxytetracycline + nystatin): clinical resolution in 10 of 10 cases in one series; intralesional / topical steroids yielded satisfactory improvement in another[24][23]
- Topical calcineurin inhibitors — tacrolimus 0.1% BID with good results in 4 weeks in a 9-patient series; option for recalcitrant cases[21][25]
- Topical mupirocin — case report of resolution with monotherapy over 3 months[22]
Labial adhesions
Common in prepubertal girls; topical corticosteroids are an alternative to topical estrogen for symptomatic cases.[26][27]
- Myers 2006 — betamethasone 0.05% cream achieved complete resolution in 68% (13/19), including estrogen-failure patients; 85% single-course response[27]
- Huseynov 2020 classification — betamethasone valerate 0.1% achieved 100% in type I (2 wk) and 80% in type II (3 wk); ineffective in type III–IV (thick dense adhesions)[28]
- Mayoglou 2009 — betamethasone separated adhesions faster (1.3 vs 2.2 mo) with fewer recurrences and fewer side effects than topical estrogen[29]
- Dowlut-McElroy 2019 RCT — lateral traction + topical estrogen > emollient for adhesion severity, but complete resolution rates not different (36% vs 19%; p = 0.21)[30]
NASPAG 2015: for symptomatic labial adhesions, topical estrogen and/or steroid cream is often curative; surgical separation for failures; recurrence common until puberty.[26]
Intralesional and intravesical triamcinolone in urology
IC/BPS with Hunner lesions
AUA IC/BPS guideline 2022 (Recommendation; Grade C): if Hunner lesions are present, fulguration with electrocautery and/or injection of triamcinolone should be performed. One of the few IC/BPS therapies producing months-long improvement after a single procedure.[31]
Bladder instillation — negative and comparative data
- Cardenas-Trowers 2021 RCT (n = 90) — adding triamcinolone to a standard BTH instillation did not improve symptoms vs standard (OLS change −6.7 vs −5.8; p = 0.31)[32]
- Moss 2023 RCT (n = 83 newly diagnosed IC/PBS) — DMSO + triamcinolone provided greater pain and nocturia improvement than BTH[33]
See Intralesional corticosteroids and Intravesical IC/BPS agents for the broader instillation framework.
Adverse effects on genital skin
Genital skin is particularly susceptible — thin and occlusive environment.[5][6]
| Adverse effect | Risk on genital skin | Clinical significance |
|---|---|---|
| Skin atrophy | High | Most concerning; worse with higher potency, longer duration, and occlusion |
| Striae | Moderate | Irreversible once formed |
| Telangiectasia | Moderate | Cosmetically concerning |
| Hypopigmentation | Low–moderate | More apparent in darker skin tones |
| Red-scrotum syndrome | Low | Persistent redness after prolonged TCS use |
| Secondary infection | Low | Candida or bacterial superinfection |
| Contact sensitization | Rare | Usually vehicle components |
| HPA-axis suppression | Very rare with genital use | Risk with clobetasol ≥2 g/day; limit ≤50 g/week total[34] |
| Folliculitis / acneiform eruption | Low | More common with occlusion |
Safety guidelines[5][34]
| Potency | Genital duration limit |
|---|---|
| Super-high (I) | 2–3 consecutive weeks on genital skin; LS is an exception with monitoring |
| High (II) | Up to 12 weeks with monitoring |
| Medium (III–V) | Up to 12 weeks |
| Low (VI–VII) | No specified limit; appropriate for maintenance |
- Clobetasol total dose ≤50 g/week; FDA label states "not for face, groin, or axillae" — routinely overridden for LS per guideline recommendation[34]
- Children more susceptible to systemic effects (higher BSA-to-weight ratio)[5][34]
Second-line — topical calcineurin inhibitors
When steroids fail or steroid-sparing is needed for maintenance:[3][14][21]
| Agent | Concentration | Key advantages | Key disadvantages | Best indications |
|---|---|---|---|---|
| Tacrolimus ointment | 0.03%, 0.1% | No atrophy; effective for LS, LP, Zoon | Burning / stinging; theoretical FDA black-box malignancy concern | Steroid-refractory LS; vulvovaginal LP; Zoon balanitis; psoriasis maintenance |
| Pimecrolimus cream | 1% | No atrophy; less burning than tacrolimus | Less effective than clobetasol for LS (investigator-rated); variable Zoon results | Mild LS maintenance; psoriasis; steroid-sparing |
See Topical calcineurin inhibitors for the dedicated deep-dive.
Prescribing summary by condition
| Condition | First-line | Potency | Regimen | Duration | Second-line |
|---|---|---|---|---|---|
| Phimosis (pediatric) | Betamethasone 0.05% ointment | II–III | BID + gentle retraction | 4–8 wk | Repeat course → circumcision[1][10] |
| Phimosis (adult) | Betamethasone 0.05% ointment | II–III | BID + gentle retraction | 4–8 wk | Circumcision / preputioplasty[11] |
| Lichen sclerosus / BXO | Clobetasol 0.05% ointment | I | BID × 4–8 wk → taper → maintenance 1–2×/wk | Indefinite | Tacrolimus 0.1%; intralesional triamcinolone; circumcision (male)[3][14] |
| Lichen planus (genital) | Clobetasol 0.05% ointment | I | BID until regress | Variable | Tacrolimus 0.1%; systemic therapy[16][17] |
| Genital psoriasis | Hydrocortisone 1–2.5% | VI–VII | BID during flare → 2×/wk | Intermittent | Calcineurin inhibitors; calcipotriene[18] |
| Zoon balanitis | Trimovate or moderate TCS | III–V | BID | 4–8 wk | Tacrolimus 0.1%; circumcision (curative)[23][24] |
| Labial adhesions | Betamethasone 0.05% cream | II | BID + lateral traction | 4–6 wk (may repeat) | Topical estrogen; surgical separation[27] |
| Contact dermatitis (genital) | Low-to-medium TCS | V–VII | BID | 1–2 wk | Remove irritant; emollients |
| Lichen simplex chronicus | Medium-to-high TCS | II–IV | BID | Until itch-scratch cycle breaks | Oral antipruritic; behavioral modification |
| IC/BPS Hunner lesions | Intralesional triamcinolone | — | At cystoscopy | Single procedure; repeat as needed | Fulguration[31] |
Evidence Summary
| Indication | Evidence level | Key source |
|---|---|---|
| Phimosis resolution | Level 1 (Cochrane) | Moreno 2024 Cochrane[1] |
| Phimosis agent selection | Level 1 (network meta) | Sridharan 2021[8]; Yang 2005[9] |
| Severe-phimosis response | Level 2 | Campos 2026 multicenter cohort[10] |
| LS first-line | Level 1 (Cochrane + guideline) | Chi 2011 Cochrane[14]; German S3 2026[13]; ACOG 224[3] |
| Male LS conservative management | Level 2 (SR) | Shieh 2024[2] |
| Lichen planus | Level 2 | Le Cleach 2012[16] |
| Zoon balanitis | Level 3 | Kyriakou 2014[21]; Tang 2001[24] |
| Labial adhesions | Level 2 | Myers 2006[27]; Huseynov 2020[28] |
| IC/BPS Hunner lesions | Guideline (AUA Grade C) | Clemens 2022[31] |
Clinical Positioning
- Topical corticosteroids are first-line for phimosis — cost-effective vs primary circumcision, Cochrane complete-resolution RR 2.73 at 4–8 weeks and RR 4.09 at ≥6 months. Moderate-potency agents (betamethasone 0.05%) are as effective as super-potent agents; hydrocortisone is reasonable if prioritizing safety.[1][8][9]
- Altered preputial skin appearance predicts failure (29% success vs 72% with healthy skin) — it signals underlying BXO, and those patients often need circumcision.[10]
- LS requires indefinite maintenance. Induction with clobetasol 0.05% ointment BID × 4–8 weeks, taper, then 1–2×/week indefinitely — stopping leads to relapse and progressive scarring.[3][14]
- Ointment > cream on genital skin — better barrier, fewer irritants, better delivery.[5][7]
- Do not use topical testosterone, DHT, or progesterone for LS — Cochrane shows no benefit, and topical testosterone actually worsened symptoms as maintenance after clobetasol.[14]
- Always biopsy atypical or refractory lesions — SCC risk in LS is real, and ACOG recommends vulvar biopsy for any atypical, refractory, or worsening lesion.[3]
- Zoon balanitis is curative with circumcision — medical therapy (Trimovate, tacrolimus) is appropriate if circumcision is declined.[23][24]
- Labial adhesions: betamethasone 0.05% cream is faster and has fewer AEs than topical estrogen (Mayoglou) — first-line in symptomatic prepubertal girls.[27][29]
- Genital psoriasis uses low-potency steroids, not high — use calcineurin inhibitors for maintenance.[18]
- Safety ceiling: super-potent TCS limited to 2–3 consecutive weeks on genital skin outside LS; clobetasol ≤ 50 g/week total.[5][34]
- Intralesional triamcinolone is the instillation-adjacent indication of note — AUA Grade C for Hunner lesions; adding it to standard BTH does not improve outcomes beyond it (Cardenas-Trowers RCT).[31][32]
See Also
- Topical calcineurin inhibitors
- Intralesional corticosteroids
- Platelet-rich plasma
- Antimitotics / antifibrotics
- Lichen sclerosus (clinical)
- Buried penis (clinical)
References
1. Moreno G, Ramirez C, Corbalán J, et al. "Topical corticosteroids for treating phimosis in boys." Cochrane Database Syst Rev. 2024;1:CD008973. doi:10.1002/14651858.CD008973.pub3
2. Shieh C, Hakam N, Pearce RJ, et al. "Conservative management of penile and urethral lichen sclerosus: a systematic review." J Urol. 2024;211(3):354–363. doi:10.1097/JU.0000000000003804
3. American College of Obstetricians and Gynecologists. "Diagnosis and management of vulvar skin disorders: ACOG Practice Bulletin No. 224." Obstet Gynecol. 2020;136(1):222–225. doi:10.1097/AOG.0000000000003945
4. Teichman JMH, Mannas M, Elston DM. "Noninfectious penile lesions." Am Fam Physician. 2018;97(2):102–110.
5. Stacey SK, McEleney M. "Topical corticosteroids: choice and application." Am Fam Physician. 2021;103(6):337–343.
6. Sidbury R, Alikhan A, Bercovitch L, et al. "Guidelines of care for the management of atopic dermatitis in adults with topical therapies." J Am Acad Dermatol. 2023;89(1):e1–e20. doi:10.1016/j.jaad.2022.12.029
7. Ringel NE, Iglesia C. "Common benign chronic vulvar disorders." Am Fam Physician. 2020;102(9):550–557.
8. Sridharan K, Sivaramakrishnan G. "Topical corticosteroids for phimosis in children: a network meta-analysis of randomized clinical trials." Pediatr Surg Int. 2021;37(8):1117–1125. doi:10.1007/s00383-021-04906-1
9. Yang SS, Tsai YC, Wu CC, Liu SP, Wang CC. "Highly potent and moderately potent topical steroids are effective in treating phimosis: a prospective randomized study." J Urol. 2005;173(4):1361–1363. doi:10.1097/01.ju.0000156556.11235.3f
10. Campos JM, Ceballos V, Torres AF, et al. "Topical steroids are effective even in severe phimosis: evidence from a multicenter cohort." J Pediatr Surg. 2026;61(7):163093. doi:10.1016/j.jpedsurg.2026.163093
11. Lygas A, Joshi HB. "An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis: a systematic review of the evidence." Expert Opin Pharmacother. 2022;23(9):1115–1122. doi:10.1080/14656566.2022.2075697
12. Nguyen ATM, Holland AJA. "Balanitis xerotica obliterans: an update for clinicians." Eur J Pediatr. 2020;179(1):9–16. doi:10.1007/s00431-019-03516-3
13. Kirtschig G, Woelber L, Günthert A, et al. "Evidence- and consensus-based guideline on lichen sclerosus." J Dtsch Dermatol Ges. 2026;24(4):566–584. doi:10.1111/ddg.70000
14. Chi CC, Kirtschig G, Baldo M, et al. "Topical interventions for genital lichen sclerosus." Cochrane Database Syst Rev. 2011;(12):CD008240. doi:10.1002/14651858.CD008240.pub2
15. Chi CC, Kirtschig G, Baldo M, et al. "Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus." J Am Acad Dermatol. 2012;67(2):305–312. doi:10.1016/j.jaad.2012.02.044
16. Le Cleach L, Chosidow O. "Lichen planus." N Engl J Med. 2012;366(8):723–732. doi:10.1056/NEJMcp1103641
17. Usatine RP, Tinitigan M. "Diagnosis and treatment of lichen planus." Am Fam Physician. 2011;84(1):53–60.
18. Menter A, Korman NJ, Elmets CA, et al. "Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions." J Am Acad Dermatol. 2011;65(1):137–174. doi:10.1016/j.jaad.2010.11.055
19. Armstrong AW, Read C. "Pathophysiology, clinical presentation, and treatment of psoriasis: a review." JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
20. Le Cleach L, Afach S, Veroniki AA, et al. "Topical treatments for chronic plaque psoriasis." Cochrane Database Syst Rev. 2026;3:CD016336. doi:10.1002/14651858.CD016336
21. Kyriakou A, Patsatsi A, Patsialas C, Sotiriadis D. "Therapeutic efficacy of topical calcineurin inhibitors in plasma cell balanitis: case series and review of the literature." Dermatology. 2014;228(1):18–23. doi:10.1159/000357153
22. Lee MA, Cohen PR. "Zoon balanitis revisited: report of balanitis circumscripta plasmacellularis resolving with topical mupirocin ointment monotherapy." J Drugs Dermatol. 2017;16(3):285–287.
23. Yoganathan S, Bohl TG, Mason G. "Plasma cell balanitis and vulvitis (of Zoon): a study of 10 cases." J Reprod Med. 1994;39(12):939–944.
24. Tang A, David N, Horton LW. "Plasma cell balanitis of Zoon: response to Trimovate cream." Int J STD AIDS. 2001;12(2):75–78. doi:10.1258/0956462011916811
25. Moreno-Arias GA, Camps-Fresneda A, Llaberia C, Palou-Almerich J. "Plasma cell balanitis treated with tacrolimus 0.1%." Br J Dermatol. 2005;153(6):1204–1206. doi:10.1111/j.1365-2133.2005.06945.x
26. Bacon JL, Romano ME, Quint EH. "Clinical recommendation: labial adhesions." J Pediatr Adolesc Gynecol. 2015;28(5):405–409. doi:10.1016/j.jpag.2015.04.010
27. Myers JB, Sorensen CM, Wisner BP, et al. "Betamethasone cream for the treatment of pre-pubertal labial adhesions." J Pediatr Adolesc Gynecol. 2006;19(6):407–411. doi:10.1016/j.jpag.2006.09.005
28. Huseynov M, Hakalmaz AE. "Labial adhesion: new classification and treatment protocol." J Pediatr Adolesc Gynecol. 2020;33(4):343–348. doi:10.1016/j.jpag.2020.03.005
29. Mayoglou L, Dulabon L, Martin-Alguacil N, Pfaff D, Schober J. "Success of treatment modalities for labial fusion: a retrospective evaluation of topical and surgical treatments." J Pediatr Adolesc Gynecol. 2009;22(4):247–250. doi:10.1016/j.jpag.2008.09.003
30. Dowlut-McElroy T, Higgins J, Williams KB, Strickland JL. "Treatment of prepubertal labial adhesions: a randomized controlled trial." J Pediatr Adolesc Gynecol. 2019;32(3):259–263. doi:10.1016/j.jpag.2018.10.006
31. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756
32. Cardenas-Trowers OO, Abraham AG, Dotson TK, et al. "Bladder instillations with triamcinolone acetonide for interstitial cystitis–bladder pain syndrome: a randomized controlled trial." Obstet Gynecol. 2021;137(5):810–819. doi:10.1097/AOG.0000000000004348
33. Moss NP, Chill HH, Sand PK, et al. "A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS)." Neurourol Urodyn. 2023;42(3):615–622. doi:10.1002/nau.25142
34. US Food and Drug Administration. Clobetasol propionate — prescribing information. Updated 2025-08-22.